Risk of Acute Kidney Injury with concomitant use of Fluoroquinolones and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers

Risk of Acute Kidney Injury with concomitant use of Fluoroquinolones and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with Angiotensin Converting Enzyme Inhibitors (ACEIs) Angiotensin receptor blockers (ARBs) and fluoroquinolones.

2019 Jul

Download latest version
File Type: pdf
Category: Communication To Health Care Professionals
Unit: pharmacovigilance